Literature DB >> 25483509

The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Gary W Zlotnick1, Thomas R Jones, Paul Liberator, Li Hao, Shannon Harris, Lisa K McNeil, Duzhang Zhu, John Perez, Joseph Eiden, Kathrin U Jansen, Annaliesa S Anderson.   

Abstract

Vaccines have had a major impact on the reduction of many diseases globally. Vaccines targeted against invasive meningococcal disease (IMD) due to serogroups A, C, W, and Y are used to prevent these diseases. Until recently no vaccine had been identified that could confer broad protection against Neisseria meningitidis serogroup B (MnB). MnB causes IMD in the very young, adolescents and young adults and thus represents a significant unmet medical need. In this brief review, we describe the discovery and development of a vaccine that has the potential for broad protection against this devastating disease.

Entities:  

Keywords:  Neisseria meningitidis; Serogroup B; factor H binding protein; serum bactericidal assay with human complement (hSBA); vaccine

Mesh：

Substances：

Year:  2014        PMID： 25483509      PMCID： PMC4514153          DOI： 10.4161/hv.34293

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  34 in total

1.  Indirect effects by meningococcal vaccines: herd protection versus herd immunity.

Authors:  Michael Bröker
Journal:  Hum Vaccin       Date:  2011-08-01

2.  Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.

Authors:  P C Richmond; M D Nissen; H S Marshall; S B Lambert; D Roberton; W C Gruber; T R Jones; A Arora
Journal:  Vaccine       Date:  2012-08-05       Impact factor: 3.641

4.  Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.

Authors:  Helen S Marshall; Peter C Richmond; Michael D Nissen; Qin Jiang; Annaliesa S Anderson; Kathrin U Jansen; Graham Reynolds; John B Ziegler; Shannon L Harris; Thomas R Jones; John L Perez
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

5.  Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Authors:  Julie A Bettinger; David W Scheifele; Scott A Halperin; Wendy Vaudry; Jamie Findlow; Ray Borrow; Duccio Medini; Raymond Tsang
Journal:  Vaccine       Date:  2013-04-12       Impact factor: 3.641

6.  Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Authors:  Monica Konar; Dan M Granoff; Peter T Beernink
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

7.  A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.

Authors:  Helen S Marshall; Peter C Richmond; Michael D Nissen; Ann Wouters; James Baber; Qin Jiang; Annaliesa S Anderson; Thomas R Jones; Shannon L Harris; Kathrin U Jansen; John L Perez
Journal:  Vaccine       Date:  2013-01-24       Impact factor: 3.641

8.  A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.

Authors:  Eric A Sheldon; Howard Schwartz; Qin Jiang; Peter C Giardina; John L Perez
Journal:  Hum Vaccin Immunother       Date:  2012-07-01       Impact factor: 3.452

9.  A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.

Authors:  Susan K Hoiseth; Ellen Murphy; Lubomira Andrew; Ulrich Vogel; Matthias Frosch; Wiebke Hellenbrand; Raquel Abad; Julio A Vazquez; Ray Borrow; Jamie Findlow; Muhamed-Kheir Taha; Ala-Eddine Deghmane; Dominique A Caugant; Paula Kriz; Martin Musilek; Leonard W Mayer; Xin Wang; Jessica R Macneil; Laura York; Charles Y Tan; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

10.  A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.

Authors:  Michael D Nissen; Helen S Marshall; Peter C Richmond; Qin Jiang; Shannon L Harris; Thomas R Jones; Kathrin U Jansen; John L Perez
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129
View more
  26 in total

1.  Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Authors:  C Hal Jones; Naglaa Mohamed; Eduardo Rojas; Lubomira Andrew; Johanna Hoyos; Julio C Hawkins; Lisa K McNeil; Qin Jiang; Leonard W Mayer; Xin Wang; Rodica Gilca; Philippe De Wals; Louise Pedneault; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

Review 2.  Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.

Authors:  Aia Assaf-Casals; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

3.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

4.  Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.

Authors:  Eduardo Lujan; Kathleen Winter; Jillandra Rovaris; Qin Liu; Dan M Granoff
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

Review 5.  Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control.

Authors:  Paul Balmer; Laura J York
Journal:  Ther Adv Vaccines Immunother       Date:  2018-06-21

Review 6.  MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

Authors:  Matt Shirley; Muhamed-Kheir Taha
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

7.  Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Authors:  Eduardo Lujan; Elizabeth Partridge; Serena Giuntini; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

8.  A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.

Authors:  Rolando Pajon; Eduardo Lujan; Dan M Granoff
Journal:  Vaccine       Date:  2015-12-20       Impact factor: 3.641

9.  Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.

Authors:  Henju Marjuki; How-Yi Chang; Nadav Topaz; Melissa J Whaley; Jeni Vuong; Alexander Chen; Laurel T Jenkins; Fang Hu; Susanna Schmink; Adam C Retchless; Jennifer D Thomas; Anna M Acosta; Lucy A McNamara; Heidi M Soeters; Sarah Mbaeyi; Xin Wang
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

Review 10.  Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

Authors:  Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer
Journal:  Vaccine       Date:  2020-08-30       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.